



| Date of submission of the dossier  Number of files  |  |  |  |  |
|---|--|--|--|--|
|   |  |  |  |  |
| Number of files   |  |  |  |  |
|   |  |  |  |  |
| Name of First Assessor  |  |  |  |  |
| Name of Second Assessor   |  |  |  |  |
| Date of first Assessment  |  |  |  |  |
| Date of second Assessment   |  |  |  |  |
| Outcome of the assessment   |  |  |  |  |
| 1.0 ADMINISTRATIVE INFORMATION  |  |  |  |  |
| 1.1 Type of the product application (tick as appropriate)   |  |  |  |  |
| Antiseptic  |  |  |  |  |
| Disinfectant  |  |  |  |  |
| Medicated Soap  |  |  |  |  |
| 1.2 Proprietary Name of the product   |  |  |  |  |
| <ul><li>1.3 Generic name of the product</li><li>1.4 Name and strength of active substance(s)</li></ul>                          |  |  |  |  |
| Name and strength of active substance(s)  |  |  |  |  |
| Name and address (physical and postal) of Applicant and Local Technical Representative  |  |  |  |  |
| Name and address (physical and postal) of Applicant   |  |  |  |  |
| 1.5.1 Name and address (physical and postal) of Applicant (Company) Name:   |  |  |  |  |
| Address:  |  |  |  |  |
| Country:  |  |  |  |  |
| Telephone:  |  |  |  |  |
| Telefax:  |  |  |  |  |
| E-Mail:   |  |  |  |  |
| 1.5.2 Name and address (physical and postal) of Local Technical Representative  |  |  |  |  |
| (Company) Name:   |  |  |  |  |
| Address:  |  |  |  |  |
| Country:  |  |  |  |  |
| Telephone:  |  |  |  |  |
| Telefax:  |  |  |  |  |
| E-Mail:   |  |  |  |  |
| 1.6. Form of the product: ☐Solution ☐Suspension ☐Gel ☐Aerosol ☐Emulsion ☐Gaseous ☐Powder ☐Bar ☐Tablet ☐ Cream ☐Others – specify | Form of the product: Solution Suspension Gel Aerosol Emulsion Gaseous Powder Bar Tablet Cream Others – specify |  |  |  |
| 1.6.1 Intended use:   |  |  |  |  |
| 1.7 Packing/pack size:  | Packing/pack size:   |  |  |  |
| 1.8 Visual description  |  |  |  |  |
| 1.9 Proposed shelf life (in months):  |  |  |  |  |
| Proposed shelf life (after reconstitution or dilution):   |  |  |  |  |
| 1.9.2 Proposed shelf life (after first opening container):  |  |  |  |  |





| 1.9.3                               | Proposed storage conditions:   |   |  |  |  |  |  |
|-------------------------------------|--|---|--|--|--|--|--|
| 1.9.4                               | Proposed storage conditions after first opening:   |   |  |  |  |  |  |
| 1.10                                | Other sister products registered or applied for registration   |   |  |  |  |  |  |
| 1.10.1                              | Do you hold Marketing Authorization (s) of other product (s) containing the same active substance (s) in the TMDA? Yes/No If yes state; Product name (s), strength (s), pharmaceutical form (s): |   |  |  |  |  |  |
|                                     | Indication(s):   |   |  |  |  |  |  |
| 1.10.2                              |  |   |  |  |  |  |  |
| 1.11                                | Distribution category: Pharmacy Only  General sale Others  |   |  |  |  |  |  |
| 1.12                                | Country of manufacture:  |   |  |  |  |  |  |
| 1.13                                | Product Marketing Authorisation in the country of manufacture. If not  |   |  |  |  |  |  |
|                                     | registered/licensed state reaso  |   |  |  |  |  |  |
| Autho                               |  | Withdrawn (by applicant after authorisation)            |  |  |  |  |  |
| Country                             |  | Country:  |  |  |  |  |  |
| Date of authorisation (dd-mm-yyyy): |  | Date of withdrawal (dd-mm-yyyy):                        |  |  |  |  |  |
| •                                   | ary name:  | Proprietary name:                                       |  |  |  |  |  |
|                                     | sation number:   | Reason for withdrawal:                                  |  |  |  |  |  |
| Refu                                | sed  | Suspended/revoked (by competent authority)              |  |  |  |  |  |
| Country:                            |  | Country:  |  |  |  |  |  |
| Date of refusal (dd-mm-yyyy):       |  | date of suspension/revocation (dd-mm-yyyy):             |  |  |  |  |  |
| Reason for Refusal:                 |  | Reason for suspension/revocation:                       |  |  |  |  |  |
|                                     |  | Proprietary name:                                       |  |  |  |  |  |
| 1.14                                |  | al address(es) of the manufacturer(s)                   |  |  |  |  |  |
| 1.14.1                              |  | (es) of the manufacturing site of the finished product. |  |  |  |  |  |
| •                                   | mpany name:  |   |  |  |  |  |  |
| •                                   | sical address:   |   |  |  |  |  |  |
|                                     | al address:  |   |  |  |  |  |  |
| Country                             | · ·  |   |  |  |  |  |  |
| Telepho                             |  |   |  |  |  |  |  |
| Telefax:                            |  |   |  |  |  |  |  |
| E-Mail:                             |  |   |  |  |  |  |  |
|                                     | 1.14.2 Name(s) and physical address(es) of the manufacturer(s) of the active substance(s)  |   |  |  |  |  |  |
| Company name:                       |  |   |  |  |  |  |  |
| Physica                             | l address:   |   |  |  |  |  |  |

**Effective Date: 21/10/2022** 





| Postal: | address:   |                        |                  |                            |                       |  |  |
|---------|--|------------------------|------------------|----------------------------|-----------------------|--|--|
| Country | Country:   |                        |                  |                            |                       |  |  |
| Teleph  | Telephone:   |                        |                  |                            |                       |  |  |
| Telefax | Telefax:   |                        |                  |                            |                       |  |  |
| E-Mail: |  |                        |                  |                            |                       |  |  |
| 1.15    |  |                        |                  |                            |                       |  |  |
|         | A note should be given as to which quantity the composition refers (e.g. ml or g). |                        |                  |                            |                       |  |  |
|         |  |                        |                  |                            | - 9/                  |  |  |
| Name    | Name of active Reference/monog Quantity Quantity per batch Reasons of              |                        |                  |                            | Reasons of            |  |  |
| substa  | ostance(s)* raph standard /unit (ml, g) inclusion                                  |                        | inclusion        |                            |                       |  |  |
|         |  |                        |                  |                            |                       |  |  |
|         |  |                        |                  |                            |                       |  |  |
| 1.      |  |                        |                  |                            |                       |  |  |
| 2.      |  |                        |                  |                            |                       |  |  |
| 3.      |  |                        |                  |                            |                       |  |  |
| e.t.c   | <b>—</b>   |                        |                  |                            |                       |  |  |
|         | Excipient(s)   |                        | T                | T                          |                       |  |  |
| 1.      |  |                        |                  |                            |                       |  |  |
| 2.      |  |                        |                  |                            |                       |  |  |
| 3       |  |                        |                  |                            |                       |  |  |
| e.t.c   |  |                        |                  |                            |                       |  |  |
|         |  |                        |                  |                            |                       |  |  |
|         |  |                        |                  |                            |                       |  |  |
| 2.0 LA  | ABELLING   |                        |                  |                            |                       |  |  |
|         |  |                        |                  |                            |                       |  |  |
|         | JMMARIES   |                        |                  |                            |                       |  |  |
|         |  |                        |                  | acy and safety information |                       |  |  |
| dossie  | er. The summ   | aries should include   | sufficient infor | mation from each sectio    | n of the product      |  |  |
| dossie  | er to provide a  | an overview of the in  | formation subn   | nitted in the product doss | sier. The summaries   |  |  |
| should  | d also empha   | size critical key para | ameters of the   | product and provide disc   | cussion of key issues |  |  |
| that in | tegrates info  | rmation from section   | s in the produc  | t dossier.                 |                       |  |  |
|         |  |                        |                  |                            |                       |  |  |
|         |  |                        |                  |                            |                       |  |  |
|         |  |                        |                  |                            |                       |  |  |
|         |  |                        |                  |                            |                       |  |  |
|         |  |                        |                  |                            |                       |  |  |
| Chem    | istry, Manuf   | acturing and Contro    | ols              |                            |                       |  |  |
|         |  | _                      |                  |                            |                       |  |  |
|         |  |                        |                  |                            |                       |  |  |
|         | Chemistry  |                        |                  |                            |                       |  |  |
|         |  |                        |                  |                            |                       |  |  |
|         |  |                        |                  |                            |                       |  |  |
|         | Manufactu  | ring process           |                  |                            |                       |  |  |
|         | iviaiiuiactu   | ring process           |                  |                            |                       |  |  |

**Effective Date: 21/10/2022** 





| Quality control   |  |  |  |  |  |
|---|--|--|--|--|--|
|   |  |  |  |  |  |
| Specifications and analytical methods   |  |  |  |  |  |
| Stability studies   |  |  |  |  |  |
| Efficacy and Safety   |  |  |  |  |  |
| Efficacy  |  |  |  |  |  |
| Safety  |  |  |  |  |  |
| Data to support specific claims ( for antiseptics)  |  |  |  |  |  |
| Products used in professional food premises   |  |  |  |  |  |
| Log reduction claims  |  |  |  |  |  |
| Persistence claims  |  |  |  |  |  |
| Time kill claims  |  |  |  |  |  |
| Sterility   |  |  |  |  |  |
| 4.0 DECLARATION BY AN APPLICANT   |  |  |  |  |  |
| I, the undersigned certify that all the information in this form and accompanying documentation is correct, complete and true to the best of my knowledge.  I also agree that I shall carry out vigilance to monitor the safety of the product in the market and provide safety update reports to TMDA. |  |  |  |  |  |
| It is hereby confirmed that fees will be paid/have been paid according to the TMDA fees and regulation  Name:   |  |  |  |  |  |
| Position in the company:  |  |  |  |  |  |
| Signature:  |  |  |  |  |  |
| Date: Official stamp:   |  |  |  |  |  |
| * Note: If fees have been paid, attach proof of payment   |  |  |  |  |  |
| 110.0. Il 1000 liavo booli paia, attaoli piooi oi paymont   |  |  |  |  |  |
| Issues to be communicated to the applicant  |  |  |  |  |  |

**Effective Date: 21/10/2022**